Fatty liver disease and diabetes
Research type
Research Study
Full title
Can we improve the prediction and detection of fatty liver disease?
IRAS ID
138127
Contact name
Donald Whitelaw
Contact email
Sponsor organisation
Bradford Teaching Hospitals NHS Foundation Trust
Research summary
Non-alcoholic fatty liver disease (NAFLD, or fatty liver) is an increasingly important cause of liver damage and especially common in obesity, diabetes and among South Asian people. it is also difficult to diagnose reliably at an early stage. In our clinics we are now starting to use the FibroScan device (similar to an ultrasound probe) to assess liver fat. We propose to use this device in a range of patients attending diabetes and liver clinics, and to use the values obtained to compare with other NAFLD scoring tools. We will examine these alongside clinical and laboratory data to look at characteristics of people with different amounts of liver fat. This will allow us to compare results for people with and without diabetes (both type 1 and type 2), people of different ethnic backgrounds, and associations with obesity.
REC name
London - Bromley Research Ethics Committee
REC reference
13/LO/1718
Date of REC Opinion
29 Oct 2013
REC opinion
Favourable Opinion